Llorente Carlos, Diaz Goizueta Francisco Javier, Hernandez Virginia, de la Morena Jose Manuel, de la Peña Enrique
Servicio de Urología. Hospital Universitario Fundación Alcorcón. Madrid. España.
Arch Esp Urol. 2014 Jun;67(5):452-6.
In this article we review the most significant published papers on active surveillance in prostate cancer and present the results of our case series. We used as main response variables the percentage of patients remaining in surveillance and the oncological results presented as global, cancer specific and metastasis free survivals. Globally, in published series 71.2% of patients included in active surveillance programs, 10-year overall survival is 68% in the series with longer follow up, and cancer-specific survival varies from 97% to 100%. In our series of 144 patients with median follow up of 3.2 years, 76.3% of the patients continue on surveillance. 24 patients (15.9%) stopped surveillance due to histological progression. 5 patients (21.3%) out of the 23 undergoing surgery presented unfavorable pathological criteria on prostatectomy specimen. No patient has died or developed metastases.
在本文中，我们回顾了关于前列腺癌主动监测的最重要的已发表论文，并展示了我们病例系列的结果。我们将仍在接受监测的患者百分比以及以总生存率、癌症特异性生存率和无转移生存率表示的肿瘤学结果用作主要反应变量。总体而言，在已发表的系列研究中，主动监测项目纳入的患者中有71.2%，随访时间较长的系列研究中10年总生存率为68%，癌症特异性生存率在97%至100%之间。在我们的144例患者系列中，中位随访时间为3.2年，76.3%的患者继续接受监测。24例患者（15.9%）因组织学进展停止监测。在接受手术的23例患者中，有5例（21.3%）在前列腺切除标本上呈现出不良病理标准。没有患者死亡或发生转移。
